As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Compre este e-book e ganhe mais 1 GRÁTIS!
Formato PDF ● Páginas 444 ● ISBN 9781466579705 ● Editora CRC Press ● Publicado 2013 ● Carregável 6 vezes ● Moeda EUR ● ID 2715426 ● Proteção contra cópia Adobe DRM
Requer um leitor de ebook capaz de DRM